LABORATORY CORP OF AMERICA HOLDINGS Insider Trading for February 2020
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in LABORATORY CORP OF AMERICA HOLDINGS.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in LABORATORY CORP OF AMERICA HOLDINGS for February 2020.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Feb 25 2020 | LH | LABORATORY CORP OF ... | Wilkinson Peter J | SVP, Chief Accounti ... | Sell | S | 189.65 | 297 | 56,326 | 297 | 594 to 297 (-50.00 %) |
Feb 21 2020 | LH | LABORATORY CORP OF ... | BELINGARD JEAN-LUC | Director | Option Exercise | M | 77.19 | 3,100 | 239,289 | 0 | |
Feb 21 2020 | LH | LABORATORY CORP OF ... | BELINGARD JEAN-LUC | Director | Sell | S | 189.76 | 26,479 | 5,024,750 | 14,682 | 41.2 K to 14.7 K (-64.33 %) |
Feb 21 2020 | LH | LABORATORY CORP OF ... | BELINGARD JEAN-LUC | Director | Buy | M | 77.19 | 3,100 | 239,289 | 41,161 | 38.1 K to 41.2 K (+8.14 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Option Exercise | M | 0.00 | 940 | 0 | 35,650 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Option Exercise | M | 0.00 | 780 | 0 | 36,590 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Payment of Exercise | F | 187.51 | 280 | 52,503 | 18,966 | 19.2 K to 19 K (-1.45 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Buy | M | 0.00 | 940 | 0 | 19,246 | 18.3 K to 19.2 K (+5.13 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Payment of Exercise | F | 187.51 | 232 | 43,502 | 18,306 | 18.5 K to 18.3 K (-1.25 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Buy | M | 0.00 | 780 | 0 | 18,538 | 17.8 K to 18.5 K (+4.39 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Option Exercise | M | 0.00 | 283 | 0 | 8,511 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Option Exercise | M | 0.00 | 233 | 0 | 8,794 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Sell | S | 188.49 | 103 | 19,414 | 486 | 589 to 486 (-17.49 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Sell | S | 188.49 | 85 | 16,022 | 589 | 674 to 589 (-12.61 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Payment of Exercise | F | 187.51 | 78 | 14,626 | 674 | 752 to 674 (-10.37 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Buy | M | 0.00 | 283 | 0 | 752 | 469 to 752 (+60.34 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Payment of Exercise | F | 187.51 | 64 | 12,001 | 469 | 533 to 469 (-12.01 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Buy | M | 0.00 | 233 | 0 | 533 | 300 to 533 (+77.67 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | SVP, Chief Informat ... | Option Exercise | M | 0.00 | 353 | 0 | 6,768 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | SVP, Chief Informat ... | Option Exercise | M | 0.00 | 2,353 | 0 | 7,121 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | SVP, Chief Informat ... | Option Exercise | M | 0.00 | 233 | 0 | 9,474 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | SVP, Chief Informat ... | Payment of Exercise | F | 187.51 | 105 | 19,689 | 8,358 | 8.5 K to 8.4 K (-1.24 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | SVP, Chief Informat ... | Buy | M | 0.00 | 353 | 0 | 8,463 | 8.1 K to 8.5 K (+4.35 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | SVP, Chief Informat ... | Payment of Exercise | F | 187.51 | 699 | 131,069 | 8,110 | 8.8 K to 8.1 K (-7.94 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | SVP, Chief Informat ... | Buy | M | 0.00 | 2,353 | 0 | 8,809 | 6.5 K to 8.8 K (+36.45 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | SVP, Chief Informat ... | Payment of Exercise | F | 187.51 | 68 | 12,751 | 6,456 | 6.5 K to 6.5 K (-1.04 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | SVP, Chief Informat ... | Buy | M | 0.00 | 233 | 0 | 6,524 | 6.3 K to 6.5 K (+3.70 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Option Exercise | M | 0.00 | 2,353 | 0 | 14,188 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Option Exercise | M | 0.00 | 283 | 0 | 16,541 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Option Exercise | M | 0.00 | 233 | 0 | 16,824 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Payment of Exercise | F | 187.51 | 698 | 130,882 | 2,326 | 3 K to 2.3 K (-23.08 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Buy | M | 0.00 | 2,353 | 0 | 3,024 | 671 to 3 K (+350.67 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Payment of Exercise | F | 187.51 | 86 | 16,126 | 671 | 757 to 671 (-11.36 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Buy | M | 0.00 | 283 | 0 | 757 | 474 to 757 (+59.70 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Payment of Exercise | F | 187.51 | 82 | 15,376 | 474 | 556 to 474 (-14.75 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Buy | M | 0.00 | 233 | 0 | 556 | 323 to 556 (+72.14 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Wilkinson Peter J | SVP, Chief Accounti ... | Option Exercise | M | 0.00 | 680 | 0 | 2,184 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Wilkinson Peter J | SVP, Chief Accounti ... | Option Exercise | M | 0.00 | 186 | 0 | 2,864 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Wilkinson Peter J | SVP, Chief Accounti ... | Payment of Exercise | F | 187.51 | 206 | 38,627 | 594 | 800 to 594 (-25.75 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Wilkinson Peter J | SVP, Chief Accounti ... | Buy | M | 0.00 | 680 | 0 | 800 | 120 to 800 (+566.67 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Wilkinson Peter J | SVP, Chief Accounti ... | Payment of Exercise | F | 187.51 | 66 | 12,376 | 120 | 186 to 120 (-35.48 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Wilkinson Peter J | SVP, Chief Accounti ... | Buy | M | 0.00 | 186 | 0 | 186 | 0 to 186 |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Option Exercise | M | 0.00 | 316 | 0 | 10,618 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Option Exercise | M | 0.00 | 263 | 0 | 10,934 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Payment of Exercise | F | 187.51 | 88 | 16,501 | 5,061 | 5.1 K to 5.1 K (-1.71 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Buy | M | 0.00 | 316 | 0 | 5,149 | 4.8 K to 5.1 K (+6.54 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Payment of Exercise | F | 187.51 | 71 | 13,313 | 4,833 | 4.9 K to 4.8 K (-1.45 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Buy | M | 0.00 | 263 | 0 | 4,904 | 4.6 K to 4.9 K (+5.67 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | KING DAVID P | Director | Option Exercise | M | 0.00 | 4,236 | 0 | 50,558 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | KING DAVID P | Director | Option Exercise | M | 0.00 | 3,513 | 0 | 54,794 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | KING DAVID P | Director | Payment of Exercise | F | 187.51 | 1,894 | 355,144 | 313,392 | 315.3 K to 313.4 K (-0.60 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | KING DAVID P | Director | Buy | M | 0.00 | 4,236 | 0 | 315,286 | 311.1 K to 315.3 K (+1.36 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | KING DAVID P | Director | Payment of Exercise | F | 187.51 | 1,386 | 259,889 | 311,050 | 312.4 K to 311.1 K (-0.44 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | KING DAVID P | Director | Buy | M | 0.00 | 3,513 | 0 | 312,436 | 308.9 K to 312.4 K (+1.14 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | ANDERSON KERRII B | Director | Option Exercise | M | 0.00 | 1,227 | 0 | 986 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | ANDERSON KERRII B | Director | Buy | M | 0.00 | 1,227 | 0 | 19,160 | 17.9 K to 19.2 K (+6.84 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | BELINGARD JEAN-LUC | Director | Option Exercise | M | 0.00 | 1,227 | 0 | 986 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | BELINGARD JEAN-LUC | Director | Payment of Exercise | F | 187.51 | 123 | 23,064 | 38,061 | 38.2 K to 38.1 K (-0.32 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | BELINGARD JEAN-LUC | Director | Buy | M | 0.00 | 1,227 | 0 | 38,184 | 37 K to 38.2 K (+3.32 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Gilliland Dwight Gary | Director | Option Exercise | M | 0.00 | 1,227 | 0 | 986 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Gilliland Dwight Gary | Director | Buy | M | 0.00 | 1,227 | 0 | 5,766 | 4.5 K to 5.8 K (+27.03 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Kong Garheng | Director | Option Exercise | M | 0.00 | 1,227 | 0 | 986 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Kong Garheng | Director | Buy | M | 0.00 | 1,227 | 0 | 8,452 | 7.2 K to 8.5 K (+16.98 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | NEUPERT PETER M | Director | Option Exercise | M | 0.00 | 1,227 | 0 | 986 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | NEUPERT PETER M | Director | Buy | M | 0.00 | 1,227 | 0 | 9,996 | 8.8 K to 10 K (+13.99 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Parham Richelle P | Director | Option Exercise | M | 0.00 | 1,227 | 0 | 986 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Parham Richelle P | Director | Buy | M | 0.00 | 1,227 | 0 | 5,088 | 3.9 K to 5.1 K (+31.78 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Williams R Sanders | Director | Option Exercise | M | 0.00 | 1,227 | 0 | 986 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Williams R Sanders | Director | Sell | S | 188.49 | 1,227 | 231,277 | 5,095 | 6.3 K to 5.1 K (-19.41 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Williams R Sanders | Director | Buy | M | 0.00 | 1,227 | 0 | 6,322 | 5.1 K to 6.3 K (+24.08 %) |
Feb 11 2020 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Option Exercise | M | 0.00 | 297 | 0 | 9,027 | |
Feb 11 2020 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Sell | S | 181.99 | 108 | 19,655 | 300 | 408 to 300 (-26.47 %) |
Feb 11 2020 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Payment of Exercise | F | 182.33 | 82 | 14,951 | 408 | 490 to 408 (-16.73 %) |
Feb 11 2020 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Buy | M | 0.00 | 297 | 0 | 490 | 193 to 490 (+153.89 %) |
Feb 11 2020 | LH | LABORATORY CORP OF ... | van der Vaart Sandra D | SVP, Global General ... | Option Exercise | M | 0.00 | 367 | 0 | 2,330 | |
Feb 11 2020 | LH | LABORATORY CORP OF ... | van der Vaart Sandra D | SVP, Global General ... | Sell | S | 181.99 | 133 | 24,205 | 2,529 | 2.7 K to 2.5 K (-5.00 %) |
Feb 11 2020 | LH | LABORATORY CORP OF ... | van der Vaart Sandra D | SVP, Global General ... | Payment of Exercise | F | 182.33 | 101 | 18,415 | 2,662 | 2.8 K to 2.7 K (-3.66 %) |
Feb 11 2020 | LH | LABORATORY CORP OF ... | van der Vaart Sandra D | SVP, Global General ... | Buy | M | 0.00 | 367 | 0 | 2,763 | 2.4 K to 2.8 K (+15.32 %) |
Feb 11 2020 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Option Exercise | M | 0.00 | 337 | 0 | 11,197 | |
Feb 11 2020 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Payment of Exercise | F | 182.33 | 103 | 18,780 | 4,641 | 4.7 K to 4.6 K (-2.17 %) |
Feb 11 2020 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Buy | M | 0.00 | 337 | 0 | 4,744 | 4.4 K to 4.7 K (+7.65 %) |
Feb 11 2020 | LH | LABORATORY CORP OF ... | KING DAVID P | Director | Option Exercise | M | 0.00 | 4,220 | 0 | 58,307 | |
Feb 11 2020 | LH | LABORATORY CORP OF ... | KING DAVID P | Director | Payment of Exercise | F | 182.33 | 1,252 | 228,277 | 308,923 | 310.2 K to 308.9 K (-0.40 %) |
Feb 11 2020 | LH | LABORATORY CORP OF ... | KING DAVID P | Director | Buy | M | 0.00 | 4,220 | 0 | 310,175 | 306 K to 310.2 K (+1.38 %) |
Feb 11 2020 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Option Exercise | M | 0.00 | 994 | 0 | 37,370 | |
Feb 11 2020 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Payment of Exercise | F | 182.33 | 295 | 53,787 | 17,758 | 18.1 K to 17.8 K (-1.63 %) |
Feb 11 2020 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Buy | M | 0.00 | 994 | 0 | 18,053 | 17.1 K to 18.1 K (+5.83 %) |
Feb 11 2020 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | SVP, Chief Informat ... | Option Exercise | M | 0.00 | 297 | 0 | 9,707 | |
Feb 11 2020 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | SVP, Chief Informat ... | Payment of Exercise | F | 182.33 | 103 | 18,780 | 6,291 | 6.4 K to 6.3 K (-1.61 %) |
Feb 11 2020 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | SVP, Chief Informat ... | Buy | M | 0.00 | 297 | 0 | 6,394 | 6.1 K to 6.4 K (+4.87 %) |
Feb 07 2020 | LH | LABORATORY CORP OF ... | Kong Garheng | Director | Option Exercise | A | 0.00 | 986 | 0 | 2,213 | |
Feb 07 2020 | LH | LABORATORY CORP OF ... | Kong Garheng | Director | Option Exercise | A | 0.00 | 986 | 0 | 2,213 | |
Feb 06 2020 | LH | LABORATORY CORP OF ... | Williams R Sanders | Director | Option Exercise | A | 0.00 | 986 | 0 | 2,213 | |
Feb 06 2020 | LH | LABORATORY CORP OF ... | Williams R Sanders | Director | Gift | G | 0.00 | 1,791 | 0 | 5,095 | 6.9 K to 5.1 K (-26.01 %) |
Feb 06 2020 | LH | LABORATORY CORP OF ... | Parham Richelle P | Director | Option Exercise | A | 0.00 | 986 | 0 | 2,213 | |
Feb 06 2020 | LH | LABORATORY CORP OF ... | NEUPERT PETER M | Director | Option Exercise | A | 0.00 | 986 | 0 | 2,213 | |
Feb 06 2020 | LH | LABORATORY CORP OF ... | Gilliland Dwight Gary | Director | Option Exercise | A | 0.00 | 986 | 0 | 2,213 | |
Feb 06 2020 | LH | LABORATORY CORP OF ... | Davis Jeffrey A. | Director | Option Exercise | A | 0.00 | 986 | 0 | 1,159 | |
Feb 06 2020 | LH | LABORATORY CORP OF ... | BELINGARD JEAN-LUC | Director | Option Exercise | A | 0.00 | 986 | 0 | 2,213 | |
Feb 06 2020 | LH | LABORATORY CORP OF ... | ANDERSON KERRII B | Director | Option Exercise | A | 0.00 | 986 | 0 | 2,213 | |
Feb 06 2020 | LH | LABORATORY CORP OF ... | Schechter Adam H | President & CEO | Option Exercise | A | 182.51 | 45,600 | 8,322,456 | 45,600 | |
Feb 06 2020 | LH | LABORATORY CORP OF ... | Schechter Adam H | President & CEO | Option Exercise | A | 0.00 | 10,520 | 0 | 17,767 | |
Feb 06 2020 | LH | LABORATORY CORP OF ... | Seltz Judith C | Chief Human Resourc ... | Option Exercise | A | 182.51 | 3,600 | 657,036 | 3,600 | |
Feb 06 2020 | LH | LABORATORY CORP OF ... | Seltz Judith C | Chief Human Resourc ... | Option Exercise | A | 0.00 | 840 | 0 | 840 | |
Feb 06 2020 | LH | LABORATORY CORP OF ... | van der Vaart Sandra D | SVP, Global General ... | Option Exercise | A | 182.51 | 3,600 | 657,036 | 3,600 | |
Feb 06 2020 | LH | LABORATORY CORP OF ... | van der Vaart Sandra D | SVP, Global General ... | Option Exercise | A | 0.00 | 840 | 0 | 2,637 | |
Feb 06 2020 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Option Exercise | A | 182.51 | 7,300 | 1,332,323 | 7,300 | |
Feb 06 2020 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Option Exercise | A | 0.00 | 1,680 | 0 | 11,534 | |
Feb 06 2020 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Option Exercise | A | 182.51 | 7,300 | 1,332,323 | 7,300 | |
Feb 06 2020 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Option Exercise | A | 0.00 | 1,680 | 0 | 9,324 | |
Feb 06 2020 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Option Exercise | A | 182.51 | 12,600 | 2,299,626 | 12,600 | |
Feb 06 2020 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Option Exercise | A | 0.00 | 2,910 | 0 | 38,364 | |
Feb 06 2020 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Option Exercise | A | 182.51 | 7,300 | 1,332,323 | 7,300 | |
Feb 06 2020 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Option Exercise | A | 0.00 | 1,680 | 0 | 17,057 | |
Feb 06 2020 | LH | LABORATORY CORP OF ... | Wilkinson Peter J | SVP, Chief Accounti ... | Option Exercise | A | 182.51 | 1,900 | 346,769 | 1,900 | |
Feb 06 2020 | LH | LABORATORY CORP OF ... | Wilkinson Peter J | SVP, Chief Accounti ... | Option Exercise | A | 0.00 | 450 | 0 | 3,050 | |
Feb 06 2020 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | SVP, Chief Informat ... | Option Exercise | A | 182.51 | 4,900 | 894,299 | 4,900 | |
Feb 06 2020 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | SVP, Chief Informat ... | Option Exercise | A | 0.00 | 1,120 | 0 | 10,004 |